Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514717 · ClinicalTrials.gov registry record · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
A Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, sponsored by Mersana Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
- 14
- Study locations
NCT05514717 is a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer that is actively recruiting participants, run by Mersana Therapeutics. The registered enrollment target is 162 participants, below the 237-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (32% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT05514717, a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, is actively recruiting participants, sponsored by Mersana Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
Conditions Studied
Interventions
- DRUG XMT-2056
Study Locations (14)
California
- University of South California - Los Angeles
- University of California Los Angeles - Los Angeles
- Stanford University Medical Center - Stanford
New York
- New York University Medical Oncology Associates - New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- AdventHealth Celebration - Celebration
Georgia
- Emory Healthcare, Emory Clinic - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514717
The ClinicalTrials.gov registry entry for NCT05514717 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (32% lower). The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which XMT-2056 is the first listed.
NCT05514717 reports 14 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT05514717 about?
NCT05514717 is a clinical study titled "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2". A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
What is the current status of trial NCT05514717?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2023-01-24. Estimated completion is 2027-04.
What conditions does trial NCT05514717 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Low Breast Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer.
What interventions are being tested in trial NCT05514717?
The interventions under investigation include: XMT-2056 (DRUG).
Who is sponsoring clinical trial NCT05514717?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514717 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
HER2 Vaccine for Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.